Effects of cicletanine in the left circumflex coronary artery occlusion-reperfusion canine model of sudden death: analysis of 107 experiments using Cox's proportional hazards model.
Multivariate analysis of survival using Cox's proportional hazards model demonstrates that several clinically measurable covariates are determinants of life-threatening arrhythmias following left circumflex coronary artery occlusion-reperfusion in 107 dogs. These are heart rate, ST segment elevation and mean aortic pressure immediately (3 min) following occlusion, and the presence of early (0-10 min) post-occlusion sustained ventricular tachycardia. The risk of occlusion-reperfusion ventricular fibrillation was determined according to Cox's solution based on ST segment elevation, thus enabling quantification of the role of cicletanine. Since cicletanine-treated dogs had reduced mean ST segment elevation at 3 min post-occlusion, lower incidence of early post-occlusion (0-10 min) sustained ventricular tachycardia, and increased endogenous production of prostacyclin, and the latter was inversely correlated with the level of ST segment elevation, it is concluded that such favourable effects on the ischaemic myocardium were contributory to the improved outcome in these experiments. These effects on the ischaemic myocardium obtained in spite of a hypotensive action in the experimental setting might be regarded as desirable and it is therefore suggested that they should be further investigated by pharmacodynamic studies in human subjects.
Jouve
R
R
INSERM U278, University of Aix-Marseille II, School of Medicine, France.
Puddu
P E
PE
Langlet
F
F
Lanti
M
M
Guillen
J C
JC
Rolland
P H
PH
Serradimigni
A
A
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D001794:Blood Pressure; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003645:Death, Sudden / Q000209:etiology; D004232:Diuretics / Q000627:therapeutic use*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate; D006352:Heart Ventricles; D008297:Male; D010477:Perfusion; D011725:Pyridines; D013223:Statistics as Topic
D000959:Antihypertensive Agents; D004232:Diuretics; D011725:Pyridines; D015121:6-Ketoprostaglandin F1 alpha; C038068:cicletanine